Dana Miller Ervin
Dana Miller Ervin is a reporter, examining the U.S. health care system. She originally joined WFAE as a Holly and Paul Freestone Health Care Reporting Fellow.
Ervin is an award-winning journalist who has worked at “60 Minutes,” CNBC, “CBS This Morning” and “Nightline.” She has three Emmy Awards for investigative reporting and research, as well as a Peabody Award and an Alfred I. DuPont Award. Ervin has also served as a senior, nonpartisan investigator for the U.S. House Appropriations Committee, digging deep into big government programs.
-
For those living with severe mental illness, the chances of becoming homeless can be high. Once homeless, they’re more likely to end up behind bars. Going to jail can start a downward spiral. Many lose jobs or benefits — even health care. Some will cycle between jail and the streets for years — often for minor crimes like trespassing. Last week, WFAE — with support from the PBS series, "FRONTLINE" — examined the problem of inmates who wait in custody for months because they’re too sick to stand trial. This week we focus on inmates who cycle in and out of jail, serving what many in the court system call a “life sentence on the installment plan.”
-
Crisis describes North Carolina’s mental health system. It is harder to access mental health care here than most other states, and that affects everyone — particularly the most vulnerable. Like inmates who are too sick to stand trial. They often wait months in custody for the treatment they need just to be well enough to go to court.
-
The story behind Fractured, a WFAE investigation — with support from the PBS series, FRONTLINE — into the failure of North Carolina’s mental health system, and its impact on the most vulnerable.
-
In this series, legal terms are used often. Here are explanations of some of the terms.
-
Medicare's decision to limit coverage for a controversial new Alzheimer's drug has prompted an outcry among Alzheimer's advocates. The drug is Aduhelm, and despite widespread enthusiasm for it among Alzheimer's patients and advocates, it hasn't been proven to slow the disease. The drug was given accelerated approval by the Food and Drug Administration because it reduces the plaque that develops in the brains of most Alzheimer’s patients.
-
Aduhelm, an expensive Alzheimer's drug, is fomenting controversy — and generating excitement for patients. The FDA approved it last summer. But Adulem’s results are the subject of intense debate — and so is the cost of the drug.
-
Charlotte area hospitals make a profit on patient care, according to an online calculator from the National Academy for State Health Policy.
-
Private equity firms have been buying up and building out autism therapy clinics. Why?
-
North Carolina's $650 million Healthy Opportunities pilot launches Tuesday.
-
North Carolina's Healthy Opportunities Pilot will launch on March 15, allowing some patients to get assistance with food, shelter, transportation and protection from domestic violence.